Beilei Zeng

619 total citations
21 papers, 463 citations indexed

About

Beilei Zeng is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Beilei Zeng has authored 21 papers receiving a total of 463 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 12 papers in Cancer Research and 5 papers in Oncology. Recurrent topics in Beilei Zeng's work include MicroRNA in disease regulation (6 papers), Circular RNAs in diseases (6 papers) and Cancer-related molecular mechanisms research (5 papers). Beilei Zeng is often cited by papers focused on MicroRNA in disease regulation (6 papers), Circular RNAs in diseases (6 papers) and Cancer-related molecular mechanisms research (5 papers). Beilei Zeng collaborates with scholars based in China, Macao and United States. Beilei Zeng's co-authors include Guosheng Ren, Yunhai Li, Tingxiu Xiang, Hongzhong Li, Jiazheng Sun, Yushen Wu, Ziying Yi, Dejuan Yang, Juan Luo and Zhu Qiu and has published in prestigious journals such as Scientific Reports, The FASEB Journal and Biochemical and Biophysical Research Communications.

In The Last Decade

Beilei Zeng

21 papers receiving 460 citations

Peers

Beilei Zeng
Haifeng Wang China
Xisheng Liu China
Yuqi Wang China
Athanasios Ploumakis United Kingdom
Chengmeng Jin China
Di Yang China
Baofei Jiang China
Jinye Xu China
Tao Lv China
Haifeng Wang China
Beilei Zeng
Citations per year, relative to Beilei Zeng Beilei Zeng (= 1×) peers Haifeng Wang

Countries citing papers authored by Beilei Zeng

Since Specialization
Citations

This map shows the geographic impact of Beilei Zeng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beilei Zeng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beilei Zeng more than expected).

Fields of papers citing papers by Beilei Zeng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beilei Zeng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beilei Zeng. The network helps show where Beilei Zeng may publish in the future.

Co-authorship network of co-authors of Beilei Zeng

This figure shows the co-authorship network connecting the top 25 collaborators of Beilei Zeng. A scholar is included among the top collaborators of Beilei Zeng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beilei Zeng. Beilei Zeng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Deng, Meng, Yuwen Ma, Yang Yu, et al.. (2025). LncRNA CTD-2555A7.2 promotes bone formation with LncRNA-specific cascade amplification strategy. Scientific Reports. 15(1). 20687–20687. 2 indexed citations
2.
Wang, Xiaoxue, Kejia Xu, Beilei Zeng, et al.. (2024). Novel EGFR inhibitors against resistant L858R/T790M/C797S mutant for intervention of non-small cell lung cancer. European Journal of Medicinal Chemistry. 277. 116711–116711. 17 indexed citations
3.
Zeng, Beilei, et al.. (2024). Targeting non-coding RNAs to overcome osimertinib resistance in EGFR-mutated non-small cell lung cancer. Frontiers in Oncology. 14. 1442237–1442237. 2 indexed citations
4.
Yin, Chong, Meng Deng, Xudong Deng, et al.. (2024). An Andrias davidianus derived composite hydrogel with enhanced antibacterial and bone repair properties for osteomyelitis treatment. Scientific Reports. 14(1). 24626–24626. 1 indexed citations
5.
Zeng, Beilei, et al.. (2024). Brain radiation necrosis treated with bevacizumab in a patient with advanced squamous cell lung carcinoma: A case report. Oncology Letters. 29(2). 98–98. 1 indexed citations
6.
Zeng, Beilei, et al.. (2024). Norcantharidin in cancer therapy – a new approach to overcoming therapeutic resistance: A review. Medicine. 103(9). e37394–e37394. 3 indexed citations
7.
Kong, Fansheng, Yuan Zhou, Yinghua Lu, et al.. (2023). Transcriptome analysis identification of A-to-I RNA editing in granulosa cells associated with PCOS. Frontiers in Endocrinology. 14. 1170957–1170957. 4 indexed citations
8.
Yu, Yang, Ye Tian, Meng Deng, et al.. (2023). A potential therapeutic drug for osteoporosis: prospect for osteogenic LncRNAs. Frontiers in Endocrinology. 14. 1219433–1219433. 4 indexed citations
9.
10.
Wu, Yushen, Beilei Zeng, Jiazheng Sun, et al.. (2020). CircEHMT1 inhibits metastatic potential of breast cancer cells by modulating miR-1233-3p/KLF4/MMP2 axis. Biochemical and Biophysical Research Communications. 526(2). 306–313. 40 indexed citations
11.
Yi, Ziying, Yunhai Li, Yushen Wu, et al.. (2020). <p>Circular RNA 0001073 Attenuates Malignant Biological Behaviours in Breast Cancer Cell and Is Delivered by Nanoparticles to Inhibit Mice Tumour Growth</p>. OncoTargets and Therapy. Volume 13. 6157–6169. 31 indexed citations
12.
Yi, Qin, Beilei Zeng, Yixiao Feng, et al.. (2019). <p>Long noncoding RNA LINC01089 predicts clinical prognosis and inhibits cell proliferation and invasion through the Wnt/β-catenin signaling pathway in breast cancer</p>. OncoTargets and Therapy. Volume 12. 4883–4895. 35 indexed citations
13.
Wu, Yushen, et al.. (2019). A four-miRNA signature as a novel biomarker for predicting survival in endometrial cancer. Gene. 697. 86–93. 26 indexed citations
14.
Qiu, Zhu, et al.. (2018). Downregulated CDKN1C/p57kip2 drives tumorigenesis and associates with poor overall survival in breast cancer. Biochemical and Biophysical Research Communications. 497(1). 187–193. 22 indexed citations
15.
Feng, Yixiao, Mingjun Wu, Shuman Li, et al.. (2018). The epigenetically downregulated factor CYGB suppresses breast cancer through inhibition of glucose metabolism. Journal of Experimental & Clinical Cancer Research. 37(1). 313–313. 18 indexed citations
16.
Huang, Yujing, Qing Shao, Xinrong Luo, et al.. (2018). Poly(ADP‐ribose) polymerase‐1 promotes recruitment of meiotic recombination‐11 to chromatin and DNA double‐strand break repair in Ku70‐deficient breast cancer cells. The FASEB Journal. 32(11). 6112–6122. 7 indexed citations
17.
Li, Yunhai, Jing Huang, Beilei Zeng, et al.. (2018). PSMD2 regulates breast cancer cell proliferation and cell cycle progression by modulating p21 and p27 proteasomal degradation. Cancer Letters. 430. 109–122. 83 indexed citations
18.
Yang, Dejuan, Yunhai Li, Lei Xing, et al.. (2018). Utilization of adipocyte-derived lipids and enhanced intracellular trafficking of fatty acids contribute to breast cancer progression. Cell Communication and Signaling. 16(1). 32–32. 62 indexed citations
19.
Zeng, Beilei, Yunhai Li, Yixiao Feng, et al.. (2018). Downregulated miR-1247-5p associates with poor prognosis and facilitates tumor cell growth via DVL1/Wnt/β-catenin signaling in breast cancer. Biochemical and Biophysical Research Communications. 505(1). 302–308. 33 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Haifeng Wang Breakdown of academic impact, for papers by Xisheng Liu Breakdown of academic impact, for papers by Yuqi Wang Breakdown of academic impact, for papers by Athanasios Ploumakis Breakdown of academic impact, for papers by Chengmeng Jin Breakdown of academic impact, for papers by Di Yang Breakdown of academic impact, for papers by Baofei Jiang Breakdown of academic impact, for papers by Jinye Xu Breakdown of academic impact, for papers by Tao Lv
Rankless by CCL
2026